Welcome to The Multiple Sclerosis Journey. Join us for a multimedia exploration of where MS treatment and research stands, what the future of care may hold, and the experiences of clinicians and patients as they collaborate on the frontlines of MS care.
The Multiple Sclerosis Journey will examine new insights on the importance of early diagnosis as well as accurate identification of the four MS phenotypes and how their recognition impacts treatment selection. Join us as we examine the importance of maintaining brain health in sustaining wellness and ability among patients with MS. Experience discussions of the role of patient and physician collaboration in sustaining continuity of care and in tailoring therapy to individual patient needs and preferences.

And, importantly, view the impact of MS through the eyes of individual patients who generously tell their stories of how they build their lives around their abilities, not their disabilities.

The road to a cure for MS lies ahead. Along the way, clinicians, physicians, and patients are sharing their stories of working toward that goal at The Multiple Sclerosis Journey. We invite you to join them.

Walk with us.

Featured Articles

Infusible MS medications work best in younger patients

Infusible disease-modifying therapies for multiple sclerosis (MS) are disproportionately more effective at quelling disease activity than oral drugs in younger patients, an advantage that fades by about age 45 years, Enrique Alvarez, MD, PhD, reported at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Hypogammaglobulinemia and infection risk clarified in MS patients on anti-CD20 agents

Monitoring immunoglobulin levels regularly has become an imperative in patients with multiple sclerosis (MS) on anti-CD20 agents in light of consistent findings from long-term, open-label studies of rituximab and ocrelizumab presented at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Rim lesions in MS are common, prognostic, and potential treatment targets

Chronic active lesions in patients with multiple sclerosis (MS) are common, predict more aggressive disease, and occur despite disease-modifying therapy, according to a study of about 200 patients with MS.

Central vein sign on 3T MRI may be an accurate diagnostic biomarker for MS

The central vein sign detected on 3T MRI had a high sensitivity and moderate specificity in identifying cases of multiple sclerosis and differentiating them from other, similar-looking conditions, according to a recent study in JAMA Neurology.

Selma Blair goes public with her stem-cell transplant

From popular Instagram posts to the cover of People magazine, actress Selma Blair has become the face of multiple sclerosis in America this year. Her public profile emphasizes her glamour, her grit, and something else – a drastic, expensive and potentially dangerous stem-cell treatment that “reboots” the immune system. Now, neurologists are getting questions about the procedure she’s undergoing, and patients are learning that it can have dramatic impact but isn’t appropriate for many patients.